1. An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics 
Jeremy R. Johnson, BSc, MB ChB, FRCP, Dominique Lossignol, MB ChB, MRCG, DRCOG, Mary Burnell-Nugent, MB BChir, Marie T. Fallon, MB ChB, MD, FRCP (E), FRCP (Glasg) 
Journal of Pain and Symptom Management 
Volume 46, Issue 2, Pages (August 2013)
DOI: /j.jpainsymman
Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
Breakdown of patients enrolled in the study. RCT=randomized controlled trial; SAE=serious adverse event; THC=Δ9-tetrahydrocannabinol; CBD=cannabidiol; ITT=intention to treat.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
Mean Brief Pain Inventory Short-Form (BPI-SF) scores for pain severity, average pain, worst pain, and pain interference domains.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Mean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) scores for functional status domains.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4
Mean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) scores for adverse symptom domains.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions